Viewpoint

The latest Eurostat data show Europe is not delivering on the Lisbon targets. So what is to be done, asks Bruno van Pottelsberghe from the think tank Bruegel.

An OECD conference highlights the hottest trend in corporate R&D. But take heed: in business or politics, beware too much success, says Richard L. Hudson.

Call the Presidential candidates to account for science and make sure they recognise scientific issues are global, says world-leading biologist and Nobel laureate David Baltimore.

It’s tough starting a technology business anywhere – but that’s especially true in Central and Eastern Europe…and Trainingpoint’s Ivo Smelhaus talks from bitter experience.

The UK government’s minor concession on an 80 per cent increase in capital gains tax on selling start-ups won’t win back entrepreneurs

Michal Brnušàk takes a look at the obstacles – and hopes – for commercialising research in Prague.

Anti-trust legislation, particularly involving raids at dawn, is no way to improve productivity in the pharmaceutical industry, says Nuala Moran.

As Framework Programme 7 fires up, Europe’s auditors throw on some cold water. Nuala Moran wonders how we will assess whether it has all been worthwhile.

The spin-out tag makes university start-ups look weak and vulnerable, says Philip Sharpe from QinetiQ, one of Europe’s largest technology commercialisation companies.

Science|Business launches a series of news and events to prompt debate on a vital policy question: How do you encourage enterprise in science?